AAD 2023: Late-Breaking Phase III Results Demonstrate nemolizumab』s Significant Impact on Prurigo Nodularis
ZUG, Switzerland--(BUSINESS WIRE)--Galderma, the leading company solely dedicated to advancing the future of dermatology, today premiered the positive phase III results from the OLYMPIA 2 trial......